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ABSTRACT
Objective: Whitening cream is a cosmetic that contains ingredients that can alleviate hyperpigmentation. Tranexamic acid (TA) is one of the potential 
anti-pigmentation agents that work through inhibiting plasmin. TA is used in cosmetic formulations at a concentration of 2.5% as a whitening and 
moisturizing agent. To date, research on TA in both cosmetics and other pharmaceutical products using high-performance liquid chromatography 
(HPLC) has not been done directly (without derivatization). Therefore, this study aimed to develop a simple and rapid analytical method for TA 
(without derivatization) in cosmetic cream samples using reverse-phase HPLC and water as a solvent.
Methods: Optimization was conducted by evaluating several parameters that affect sample extraction, as well as composition and mobile phase 
types. The optimal method must fulfill suitability and validation requirements. The optimal method should be able to detect and quantify TA in cream 
samples without derivatization.
Results: The optimal analysis condition used a ultraviolet detector at a wavelength of 210 nm, acetonitrile: double-distilled water: phosphoric acid 
(64:34:2) as the mobile phase and a flow rate of 0.8 mL/min. The retention time of the analyte occurred in the 2nd min.
Conclusion: The analytical method that met the validation requirements was characterized using parameters such as accuracy, precision, linearity, 
selectivity, limit, of detection, and limit of quantitation. This method is applicable for analyzing TA content in samples with a concentration of 1.02%.
Keywords: Reverse-phase high-performance liquid chromatography, Optimization and validation, Tranexamic acid, Whitening cream.
INTRODUCTION
Tranexamic acid (TA) (Fig. 1) is  an antifibrinolytic agent used to 
treat menorrhagia. In addition, TA also has a whitening effect against 
hyperpigmentation caused by melasma and ultraviolet (UV) radiation [1]. 
TA has been studied for its anti-melasma potential compared with 
standard therapy [2]. These reports revealed that oral or topical TA is 
similarly effective as standard therapy in patients with melasma [3]. 
Some studies additionally stated that TA has greater efficacy with fewer 
side effects. TA has emerged as a promising treatment for melasma 
both alone and in combination with other treatments [4-6]. TA is used 
as a whitening and moisturizing agent in cosmetic formulations at a 
concentration of 2.5% [7]. According to Japanese regulations regarding 
products containing TA, a cosmetic product is considered safe as a 
whitening agent if its TA concentration does not exceed 1.5–2% [8]. 
TA can also cause severe irritation and allergies under skin conditions 
that are sensitive to the agent [9-11]. TA does not have a high number 
of chromophore groups, and thus it is difficult to detect through UV 
spectroscopy. Analyses of TA in pharmaceutical products through 
high-performance liquid chromatography (HPLC) always involve 
derivatization to obtain a higher number of chromophore groups. The 
previous studies on the derivatization of TA used derivative agents 
such as 0.2% ninhydrin in methanol [12], phenyl isothiocyanate [13], 
2-hydroxynaphthaldehyde in ethanol [14], sodium picryl sulfonate [15], 
benzenesulfonyl chloride [16], and 2,4-dinitrofluorobenzene [17]. None 
of these studies reported direct analysis using UV-HPLC. Therefore, 
this study analyzed TA content in a cosmetic sample in the form of a 
cream without derivatization using reverse-phase HPLC. The method 
of sample preparation and HPLC analysis was optimized to increase its 
sensitivity and selectivity to permit TA analysis without derivatization 
through a simpler method.
METHODS
Instrumentation
An LC 20AT HPLC system (Shimadzu, Japan) was equipped with a pump, 
SunFire™ C18 column, SPD-10A UV-Vis detector (Shimadzu), manual 
injector, and data processor (LC-Solution). A UV-Vis spectrophotometer 
(Jasco V-530), HPLC syringe (SGE, Australia), centrifuge (Labofuge 
5100), vortex (Thermo Scientific), micropipette (Eppendorf), Ultrasonic 
Sonicator, hotplate (IKA® C-MAG HS 7), pH meters (Eutech Instruments 
pH 510), and 0.45-µm Whatman filter membrane were also utilized.
Chemicals and reagents
TA (Hunan Dongting Pharmaceutical Co., Ltd.), HPLC grade acetonitrile 
(Merck), glacial acetic acid (Merck), ammonium acetate (Merck), 
double-distilled water (Ikapharmindo), potassium dihydrogen 
phosphate (Merck), methanol (Merck), and cream whitening samples 
were obtained from commercial suppliers.
Chromatographic conditions
Chromatographic separation was conducted using a C18 column as the 
stationary phase and acetonitrile: double-distilled water: phosphoric 
acid (64:34:2) v/v/v as the mobile phase at a flow rate of 0.8 mL/min. 
Chromatographic detection was performed using a UV-Vis detector at a 
wavelength of 210 nm.
Standard and working solution preparation
The standard stock solution of TA (1000 µg/mL) was prepared by 
dissolving 100 mg of TA in 70 mL of distilled water in a 100-mL 
volumetric flask. The solution was saturated for 15 min and solvent was 
added up to a volume of 100 mL. The working solution was prepared by 
diluting the stock solution with solvent to obtain 200 µg/mL TA.
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Sample preparation
Extraction was performed by dissolving 150 mg of a cream sample in 
10 mL of water and the mixture was heated at 100°C until the sample 
dissolved completely. The mixture was centrifuged at 3000 rpm for 
10 min. The supernatant was separated and filtered through a 0.45-μm 
membrane filter. Then, 20 µL of the sample were injected and the 
chromatogram was recorded.
System suitability test
In total, 20 µL of 200 µg/mL TA were injected into the HPLC system 
under the optimal analysis conditions. The injection was repeated up to 
six times. The results of each trial were recorded and used to calculate 
the coefficient of variation (CV). The required CV was ≤2% [5].
Method validation
This method is validated using parameters such as selectivity, linearity, 
limit of detection (LOD), limit of quantitation (LOQ), accuracy, and 
precision.
Selectivity
Selectivity was examined by comparing the chromatogram of a blank 
cream solution with a standard solution around the retention time of 
TA. There should be no disturbance in the retention time of TA in the 
chromatogram of the blank solution.
Linearity
Linearity tests were performed using standard solutions at six 
concentrations over the range of 150–700 µg/mL. Each concentration 
was obtained by diluting the 1000 µg/mL standard solution. The 
calibration curve plotted the relationship between the concentration 
and area using the least square method.
LOD and LOQ
LOD and LOQ were calculated using a linear regression calibration 
curve and an Sb value equal to the residual standard deviation (S[y/x]).
Accuracy and precision
Accuracy and precision tests were conducted using simulated or 
spiked placebo recovery methods. The standard number for each 
concentration of 80, 100, and 120% (16, 20, and 24 mg, respectively) 
was weighed. At each concentration, a number of matrices were added 
until a weight of 1 g was reached, and the sample was then dissolved 
in a 10-mL volumetric flask followed by extraction as described in 
the sample preparation stage. Accuracy was calculated using the 
percentage of recovery (% recovery), and precision was calculated 
using the percentage of the relative standard deviation based on three 




To determine the maximum wavelength of a compound, UV-1600 
series spectrophotometers should be used in the wavelength range of 
190–400 nm. Determination of the maximum wavelength is important 
before the start of the analysis to permit the maximum absorption of the 
compounds to be analyzed using the reverse-phase HPLC system, but 
TA does not have sufficient numbers of chromophore and auxochrome 
groups to permit direct detection using UV spectrophotometry. 
Therefore, in this study, optimization of HPLC was performed at 
wavelengths of 200, 205, and 210 nm. The results for the peak area 
and number of theoretical plates were greater at 210 nm than at the 
other wavelengths. Data from the selection of wavelength analysis of TA 
compounds are presented in Table 1.
Optimization and mobile phase composition
Mobile phase composition was optimized using three different 
mobile phases. Analysis of TA using a mobile phase consisting of 
acetonitrile: phosphate buffer pH 3.6 (35:65 v/v) produced an 
asymmetrical peak, which was not ideal because it was difficult to 
determine its area. The mobile phase of acetonitrile: double-distilled 
water: phosphate buffer (64:34:2) produced the best peak shape 
and constant. The peak was observed at 2 min, which indicated that 
the method requires a short run time. Contrarily, the mobile phase 
of methanol: buffer pH 4 (75:25) did not produce an analyte peak 
even after 15 min of analysis. The analytical process was terminated 
after 15 min because results were obtained with a faster retention 
time using acetonitrile: double-distilled water: phosphate buffer 
(64:34:2) as the mobile phase. Therefore, acetonitrile: double-distilled 
water: phosphate buffer was selected as the mobile phase because it 
provided the best area results, retention time, and peak among the 
mobile phase combinations examined. The chromatogram of the mobile 
phase optimization is presented in Fig. 2.
Optimization of the flow rate
To further optimize the conditions, three different flow rates, namely, 
0.8, 1, and 1.2 mL/min, were compared. The three flow rates resulted in 
retention times of 2.151, 1.727, and 1.435 min, respectively, and peak 
areas of 103 629, 82 545, and 103 629 µV/s, respectively.
The retention time decreased as the flow rate increased, whereas the 
area tended to become smaller because the separation did not occur 
perfectly. In addition, the pressure in the column also increased up to 
100 kgf/cm2 as the flow rate was increased. In this study, the optimal 
flow rate was 0.8 mL/min because it provided better resolution, 
a larger area, a large number of theoretical plates, a safe pressure 
Fig. 1: Structure of tranexamic acid [6]
Fig. 2: Chromatogram of the standard solution of tranexamic acid
Table 1: Wavelength analysis results
Wavelength Area (µV/s) Number of theoretical plates
200 nm 103 629 2920
93 367 3042
205 nm 110 600 3048
101 788 3068
210 nm 113 055 3171
128 553 2975
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Table 2: Optimization results for flow rate selection
Flow rate Area (mV/s) Retention time (min) Tailing factor (Tf) HETP Number of theoretical plates
0.8 103 629 2.151 1.127 51.377 2920
1.0 82 545 1.727 1.105 56.818 2640
1.2 100 705 1.435 0.739 74.85 2004
Table 3: System suitability test result




107 559 2.145 1.304 47.515 3157
1826.222 1.667269601110 499 2.143 1.351 47.754 3141
109 938 2.150 1.308 47.505 3158
110 752 2.144 1.296 48.747 3077
106 990 2.144 1.299 47.972 3127
111 464 2.148 1.45 47.515 2930
Table 4: Calibration curve data, LOD, and LOQ of tranexamic acid
Concentration (mg/mL) Area (mV/s) S (y/x) 2 S (y/x) LOD (mg/mL) LOQ (mg/mL)







LOD: Limit of detection, LOQ: Limit of quantification
Table 5: Data on the accuracy and precision of tranexamic acid content analysis in cream preparations
Concentration (µg/mL) Area (µV/s) Calculated concentration (µg/mL) SD (%) CV (%) UPK (%) Average (%)
239.8 112 720 245.0568245 1.74 1.72 102.19 101.175
108 762 237.7781456 99.15
112 700 245.0200449 102.17
300.1 141 027 297.112803 1.31 1.31 99.00 100.44
142 770 300.3181434 100.07
143 386 301.4509544 100.45
146 719 307.5802714 102.49
144 873 304.1855162 101.36
141 437 297.8667844 99.00
360.2 173 778 357.3412042 1.02 1.02 99.20 99.789
173 747 357.2841958 99.19
177 235 363.6985546 100.97
SD: Standard deviation, CV: Coefficient of variation
(70–90 kgf/cm2), and a small height equivalent of a theoretical plate 
(HETP). Chromatograms and data from the selection of flow rates for 
TA compounds are presented in Table 2.
System suitability test
Before choosing the optimal analysis conditions, it is important to first 
perform a system suitability test because there might be differences in 
the type of equipment and techniques used. The following results were 
obtained after six repeated injections: HETP, 47.515; follow-up factor, 
1304; CV, 1.667%; and number of theoretical plates, 3157. The obtained 
data met the requirements of the system suitability test because the CV 




Selectivity was evaluated using the chromatograms of blank, standard, 
and sample solutions. The results did not reveal any interference of the 
retention time for TA compounds, which was 2.145 min. Injecting 20.0 µL 
of the placebo solution (cream matrix) also resulted in no interference 
of the retention time of TA. In the placebo chromatogram (cream 
matrix), there were peaks at 0.7 and 1 min, which were considered to 
represent other compounds present in the placebo. However, no other 
peaks were observed in the chromatogram of the placebo solution 
(cream matrix). This illustrated that the analytical method was selective 
for TA compounds. The placebo solution chromatogram (cream matrix) 
is presented in Fig. 3.
Linearity
A linear regression equation was obtained using six concentrations 
of standard solutions over the range of 150–700 µg/mL, namely 
y=543.78x−20 537 with a correlation coefficient of 0.99915. From the 
results of the analysis, it can be concluded that the calibration curve 
met the linearity test requirements. Data from the linear regression are 
presented in Table 4 and the calibration curve is shown in Fig. 5.
LOD and LOQ
The LOD and LOQ identify the smallest concentrations that can be 
accurately and precisely determined using a specific method, with 
lower values indicating greater sensitivity. Both values were calculated 
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Fig. 3: Chromatogram of the cream placebo solution after 
extraction
Fig. 4: Chromatogram of a sample solution of a commercially 
available whitening cream
Fig. 5: Calibration curve of a standard solution of tranexamic acid










X 150 61 851 1.00
63 785 1.03 1.013
62 098 1.01
TA: Tranexamic acid
statistically using a linear regression line from the calibration curve. 
The LOD for TA solution was 30.225 µg/mL, whereas the LOD was 
100.85 µg/mL. The results of these analyses are presented in Table 4.
Accuracy and precision
Based on the results of the analysis, the average % recovery of TA 
at concentrations of 80, 100, and 120% was 101.175, 100.44, and 
99.789%, respectively, which all met the criterion of 98–102%. 
Furthermore, the CVs of TA at these concentrations were 1.727, 1.316, 
and 1.023%, respectively. These data also met the criteria for accuracy 
and precision, indicating that this method is suitable for analyzing TA 
content. The results for recovery and CV obtained in the accuracy test 
illustrated that the extraction method optimally separated the analyte 
from the mixture. The results of this analysis are shown in Table 5.
Determination of TA levels in whitening cream samples
The determination of a commercially available whitening cream sample 
revealed that its TA content was 1.02%. This level does not exceed the 
limit in cosmetics of 1.5–2% [2]. From the results of the analysis, it 
can be concluded that the developed method can be used to analyze 
TA content in whitening creams. The results of the level determination 
data are presented in Table 6 and Fig. 4.
CONCLUSION
The optimal conditions for analyzing TA content in whitening cream 
preparations using reverse-phase HPLC were as follows: Water solvent, 
a C18 SunFire column (4.6 mm inner diameter size, 5 µm particle size, 
and 250 mm column length), UV-Vis detector, mobile phase consisting of 
acetonitrile: double-distilled water: phosphate buffer (64:34:2 v/v/v), 
wavelength of 210 nm, and flow rate of 0.8 mL/min. The injection 
volume was 20.0 µL. The retention time of the compound peak was in 
the 2nd min.
The analytical method fulfills all of the criteria for a validation method, 
including linearity, selectivity, precision, and accuracy, and thus the 
developed method was declared valid. The method is applicable for 
analyzing whitening cream samples, as the method identified that the 
TA content in a commercially available sample was 1.02%.
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